The aim of this study was to investigate whether curcumin, dispersed with colloidal nano-particles, named Theracurmin would be more effective against Esophageal Andenocarcinomo (EAC) cells and to analyze if this new compound affects T cell response in patients undergoing immunotherapy for cancer.
Nano-curcumin significantly decreased the proliferation of the EAC cells, while not affecting the normal esophageal cell line. They also found that nano-curcumin significantly up-regulated the expression of the co-stimulatory molecule CD86 in DCs and significantly decreased the secretion of pro-inflammatory cytokines from in vitro activated T cells. When they combined T cells with nano-curcumin treatment, they found that the basic levels of T cell induced cytotoxicity of 6.4 and 4.1%, increased to 15 and 13%, respectively.
In conclusion, they found that:
“Nano-curcumin is effective against EAC, sensitizes EAC cells to T cell induced cytotoxicity and decreases the pro-inflammatory signals from T cells. Combining DC immunotherapy with nano-curcumin is potentially a promising approach for future treatment of EAC.”